Knight Therapeutics reports Q3 EPS C$0.00 vs. C$0.09 last year

Reports Q3 revenue C$92.3M vs. C$81.5M last year. “I am excited to report that for the nine months ended September 30, 2024, we delivered record revenues of over $271 million and adjusted EBITDA of over $42 million. This strong performance is the result of the growth of our key promoted products and our commercial execution across Canada and Latin America. In addition, we have advanced our pipeline with the regulatory approval of Minjuvi in Mexico with a launch expected in the first half of 2025. We remain committed to advancing our pipeline products with regulatory submissions and approvals to grow our business in Canada and Latin America.” said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics (KHTRF) Inc.